Ibrutinib Therapy - Mantle Cell Lymphoma. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organizations | Biomarkers | Cancer types | Therapies |
|---|